Study of patients with alopecia areata treated with ritlecitinib
Treatments studied
Part of Skin clinical trials.
This study follows people with alopecia areata who are starting treatment with ritlecitinib (a medication). It looks at how well the treatment works in real life and how it affects your symptoms and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older.
- A dermatologist has confirmed you have alopecia areata.
- Your doctor has prescribed ritlecitinib as part of your normal care.
- You are willing to complete questionnaires about your health and attend regular clinic visits.
- You do not have other types of hair loss (like male pattern baldness or scarring alopecia) or scalp conditions that could affect hair growth assessment.
- You have not taken ritlecitinib or any JAK inhibitor before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two different doses of a pill called ritlecitinib to see if it can help regrow hair in people with significant hair loss from alopecia areata. It is for people aged 12 and older who have lost at least half of their scalp hair.
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
This study tests an investigational oral medication (deuruxolitinib) for adolescents with severe alopecia areata (hair loss). It aims to see if it can help hair regrow safely.
This study tests if the medicine ritlecitinib can help regrow hair in people with alopecia areata, a condition that causes patchy hair loss. It's for young people and adults who have lost between 20% and 50% of their scalp hair for at least 6 months but no more than 10 years.
This Phase 2 study tests ruxolitinib to see if it safely helps regrow hair in people whose alopecia areata is linked to APECED (a rare immune condition). You may qualify if you have significant scalp hair loss for at least 6 months and haven’t had regrowth with other treatments.
This trial tests an experimental tablet for teenagers with severe alopecia areata, a condition causing patchy hair loss. The treatment may help regrow hair with clearer information about safety and effectiveness.
Hear when a new Alopecia Areata trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.